Greenfield #worldcdx Very few measure and track - but when it does happen things do change. Recruiting and promotio… https://t.co/acAmTnaca7
10:55am September 11th 2019 via Twitter Web App
Toft #worldcdx Exec search needs to reflect diversity. Increasing innovation, better financial perf (!), better talent.
10:52am September 11th 2019 via Twitter Web App
Ballmer #worldcdx Roche, Agilent: if you don't have women in the succession plan, there won't be women in leadership.
10:49am September 11th 2019 via Twitter Web App
Greenfield #worldcdx Not due to opting-out; the criteria for promotion is the same; it is SVP/C-Suite: a dramatic s… https://t.co/tA1SS8HLfE
10:48am September 11th 2019 via Twitter Web App
Greenfield #worldcdx 22% women at the board level, from 54% at entry-level. C-suite 30-something. Attrition not the problem.
10:47am September 11th 2019 via Twitter Web App
Becker #worldcdx Orgs can facilitate mentorship; Abbott hosts panels to invite meeting Sr mgmt, peer groups, to have open conversations
10:45am September 11th 2019 via Twitter Web App
Rosen #worldcdx "Million girls in STEM", J&J provides mentorship among high-schoolers.
10:44am September 11th 2019 via Twitter Web App
Rosen #worldcdx Not enough women in STEM: first is environmental (culture); then giving opportunity via programs. H… https://t.co/OMILMLKixL
10:42am September 11th 2019 via Twitter Web App
Keynote at #worldcdx on Women in Precision Medicine: Kathryn Becker Abbott Molecular; Allison Ballmer Agilent; Robi… https://t.co/0uSTe4K415
10:41am September 11th 2019 via Twitter Web App
Q: NILE study G360 mut+ respond to TKI's? Helman #worldcdx 5/6 discordant, did respond (false negative in tissue)
9:51am September 11th 2019 via Twitter Web App
Q: Move toward niche disease? Helman #worldcdx They strive for being comprehensive.
9:50am September 11th 2019 via Twitter Web App
Helman #worldcdx Shows data PFS/OS of G-Omni presented yesterday at https://t.co/9YDqA3cbJx TMB mut +/- neg predict… https://t.co/AHckLF8OMZ
9:49am September 11th 2019 via Twitter Web App
Helman #worldcdx Shows results from Kuziora AACR 2017 on I-O response and ctDNA mutation status.
9:45am September 11th 2019 via Twitter Web App
Helman #worldcdx Largest blood-based MSI to traditional tissue testing Willis CCR '19. https://t.co/kf8WNOkKhj
9:44am September 11th 2019 via Twitter Web App
Helman #worldcdx of 323 NSCLC at U Penn, 44% insuff tissue. 90% concordance via SoC tissue. 2x the muts detected.
9:40am September 11th 2019 via Twitter Web App
Helman #worldcdx More pts detected NCCN biomarkers: of >200, 77 vs 60; 9 vs 15 day TAT. Leighl '19 CCR pursuing a blood-first paradigm
9:39am September 11th 2019 via Twitter Web App
Helman #worldcdx Follow-up at Dana Farber via ddPCR, correlation chart shown. Shows results of NILE study G360 vs tissue SoC in 1L NSCLC
9:38am September 11th 2019 via Twitter Web App
Helman #worldcdx Odegaard CCR '18 chart: SNVs 0.2% drivers, fusions 0.2%, CNAs 2.24 copies, MSI 0.1%
9:36am September 11th 2019 via Twitter Web App
Helman #worldcdx Shows chart of ctDNA levels - VAF median at 0.5%. Signal gets lost in noise. Bioinf., machine learning so impt
Helman #worldcdx Key analytical validation, and full validation of CDx with narrow indication
9:35am September 11th 2019 via Twitter Web App
Helman #worldcdx FDA has an evolved oncopanel review paradigm: analytical validation by a representative approach
9:34am September 11th 2019 via Twitter Web App
Helman #worldcdx Shows testing rates from Gutieerrez '17 Clin Lung Ca across genes. G360 is 74-gene assay for mutations, 18 ampl, 6 fusion
9:33am September 11th 2019 via Twitter Web App
Helman #worldcdx 20-30% of mBC have only bone mets: 50% of bone biopsy have insuff DNA.
9:31am September 11th 2019 via Twitter Web App
Helman #worldcdx NCCN recommends genotyping across lung, breast, CRC, GIST, Prostate, Ovarian. Tissue availability: 60% lung insuff
Helman #worldcdx Medicare, strong private payer coverage. Footprint expanding; lab in CA, TX, Singapore, Japan. Working on EU, China
9:30am September 11th 2019 via Twitter Web App
Helman #worldcdx 50+ clin studies, partnership with AZ for Tagrisso and Guardant360; Imfinzi w/GuardantOmni
9:29am September 11th 2019 via Twitter Web App
Helman #worldcdx Their digital sequency: 'high-eff chemistry'. 75+ patents issued, 150+ patents pending, machine learning
9:28am September 11th 2019 via Twitter Web App
Helman #worldcdx For MRD: 56% of CRC pts referred for recurrence have not had recurrence.
9:27am September 11th 2019 via Twitter Web App
Helman #worldcdx Have 100K+ tests to-date. Late-stage Rx selection: tissue avail, exhaustion, TAT time. Only 8% of… https://t.co/yllV7oFUgc
9:26am September 11th 2019 via Twitter Web App
Helman #worldcdx Targeting the cancer care continuum: Rx selection, recurr monitoring (LUNAR-1), early det (LUNAR-2)
9:25am September 11th 2019 via Twitter Web App
Elena Helman (Guardant Health) #worldcdx Comprehensive Liquid Biopsy: Clinical & Commercial Use Cases
Q: How are CRO's adapting? Anderson #worldcdx Broad-service providers are better-equipped. Cell-based and gene-based assay dev
9:24am September 11th 2019 via Twitter Web App
Anderson #worldcdx Factors impacting delivery of Precision Med: Policy, payers, providers, prescribers, specificty, Dx/Rx industry
9:20am September 11th 2019 via Twitter Web App
Anderson #worldcdx For gene therapy: CDx oppy to look for neutralizing Abs via Elisa, or cell-based assays.
9:17am September 11th 2019 via Twitter Web App
Anderson #worldcdx With rare disease: natural history critical; KOL and pt-centric approach vital (advocacy groups).
9:15am September 11th 2019 via Twitter Web App
Anderson #worldcdx Even in CAR-T, resistance develops. Can get tumor Ag loss, or T-cell dysfunction and exhaustion.
9:12am September 11th 2019 via Twitter Web App
Anderson #worldcdx CAR-T cells eval w/cell-based assays (via flow), the molecules via qPCR, persistence, deep seq of T cell populations
9:08am September 11th 2019 via Twitter Web App
Anderson #worldcdx 1 pt, 1 product lot. A very different mfg paradigm: a real challenge. Shows cartoon of constructs
9:07am September 11th 2019 via Twitter Web App
Anderson #worldcdx Overview of CAR-T: CD19+ tumor, engineered B-cells w/scFv, how pts own T-cells are expanded ex-vivo and re-infused.
9:05am September 11th 2019 via Twitter Web App
Anderson #worldcdx Recently: Yescarta has ORR of 83%, CRR 53% for N-Cell NHL; Kymriah ORR 81%, CRR 60% for B-cell ALL
9:03am September 11th 2019 via Twitter Web App
Anderson #worldcdx expect 200 INDs each year by 2020. FDA adding 50 new clinical reviewers to enable approval of 10-20 Rx/year by 2025.
9:01am September 11th 2019 via Twitter Web App
Anderson #worldcdx For cell and gene Rx, 58% in oncology. FDA: 800 active INDs for CGT (cell and gene therapy) candidates.
9:00am September 11th 2019 via Twitter Web App
Anderson #worldcdx Cell and Gene-modified cell Rx: over 1K in development (globally), in various phases.
Anderson #worldcdx Trends: impr disease models, new Rx modalities, expanding CDx applications, lab technology, regulatory guidance
8:57am September 11th 2019 via Twitter Web App
Anderson #worldcdx in Drug Dev - probability of success: earlier implementation = better; trend: 2018 now 42% of PM… https://t.co/fOn3ZuQZyE
8:55am September 11th 2019 via Twitter Web App
Anderson #worldcdx Over 300 biomarkers in current drug labels (efficacy, dosage, AEs) PM at intersection of biomarkers, CDx, Cell/Gene Rx
8:53am September 11th 2019 via Twitter Web App
Anderson #worldcdx Drivers for implementation of Precision Medicine: ~40 CDx on market today. All but one for oncology. 4 approved for CAR-T
8:52am September 11th 2019 via Twitter Web App
Steve Anderson (Covance) #worldcdx The Evolving Precision Medicine Landscape: The role of biomarkers, CDx and advanced therapies
8:51am September 11th 2019 via Twitter Web App
Q: What about different populations? Haviland #worldcdx Very similar criteria; quality, TAT, feasibility of implementation.
8:49am September 11th 2019 via Twitter Web App
Haviland #worldcdx (Observes a moment of silence in honor of 9/11.)
8:47am September 11th 2019 via Twitter Web App
